Synergy in activating class I PI3Ks

Trends in Biochemical Sciences

Volumn 40, Issue 2, 2015, Pages 88-100

  Burke, John E ^a   Williams, Roger L ^b  

^a UNIVERSITY OF VICTORIA   (Canada)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

Cancer; Lipid kinases; Lipid signaling; Phosphoinositide 3 kinases; Phosphoinositides; Primary immunodeficiencies

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; IDELALISIB; INSULIN RECEPTOR SUBSTRATE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN CDC42; PROTEIN P110; PROTEIN P85; PROTEIN TYROSINE KINASE; RAC1 PROTEIN; RAS PROTEIN; ISOPROTEIN; PHOSPHATIDYLINOSITOL;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; CARCINOGENESIS; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; GENE MUTATION; HUMAN; IMMUNOPATHOLOGY; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; CELL MOTION; ENZYMOLOGY; GENETICS; METABOLISM; NEOPLASM;

CELL MOVEMENT; CELL PROLIFERATION; HUMANS; IMMUNE SYSTEM DISEASES; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHATIDYLINOSITOLS; PROTEIN ISOFORMS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84921608353     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2014.12.003     Document Type: Review

References (109)

1. Toker A. Achieving specificity in Akt signaling in cancer. Adv. Biol. Regul. 2012, 52:78-87.
2. Kok K., et al. Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem. Sci. 2009, 34:115-127.
3. Samuels Y., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
4. Liu P., et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 2009, 8:627-644.
5. Kang S., et al. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:1289-1294.
6. Edling C.E., et al. Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin. Cancer Res. 2010, 16:4928-4937.
7. Hirsch E., et al. PI3K in cancer-stroma interactions: bad in seed and ugly in soil. Oncogene 2013, 33:3083-3090.
8. Schmid M.C., et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression. Cancer Cell 2011, 19:715-727.
9. Ali K., et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 2014, 510:407-411.
10. Soler A., et al. Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis. J. Exp. Med. 2013, 210:1937-1945.
11. Lucas C.L., et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110δ result in T cell senescence and human immunodeficiency. Nat. Immunol. 2014, 15:88-97.
12. Angulo I., et al. Phosphoinositide 3-kinase δ gene mutation predisposes to respiratory infection and airway damage. Science 2013, 342:866-871.
13. Lindhurst M.J., et al. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat. Genet. 2012, 44:928-933.
14. Rivière J-B., et al. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat. Genet. 2012, 44:934-940.
15. Kurek K.C., et al. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am. J. Hum. Genet. 2012, 90:1108-1115.
16. Jia S., et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008, 454:776-779.
17. Ciraolo E., et al. Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci. Signal. 2008, 1:1-13.
18. Knight Z., et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 2006, 125:733-747.
19. Smith G.C., et al. Extended treatment with selective PI 3-kinase and mTOR inhibitors has effects on metabolism, growth, behaviour and bone strength. FEBS J. 2013, 280:5337-5349.
20. Fruman D.A., Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Discov. 2014, 13:140-156.
21. Rodon J., et al. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 2013, 10:143-153.
22. Hoellenriegel J., et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011, 118:3603-3612.
23. Gopal A.K., et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 2014, 370:1008-1018.
24. Furman R.R., et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 2014, 370:997-1007.
25. Kahl B.S., et al. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood 2014, 123:3398-3405.
26. Brown J.R., et al. Idelalisib, an inhibitor of phosphatidylinositol 3 kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014, 123:3390-3397.
27. Flinn I.W., et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014, 123:3406-3413.
28. Juric D., et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature 2014, Published online November 17, 2014. http://dx.doi.org/10.1038/nature13948.
29. Dbouk H.A., et al. G protein-coupled receptor-mediated activation of p110β by Gβγ is required for cellular transformation and invasiveness. Sci. Signal. 2012, 5:ra89.
30. Fritsch R., et al. RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 2013, 153:1050-1063.
31. Castellano E., Downward J. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer 2011, 2:261-274.
32. Zhao J.J., et al. The p110alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:16296-16300.
33. Foukas L., et al. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 2006, 441:366-370.
34. Juvin V., et al. Signaling via class IA phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines. PLoS ONE 2013, 8:e75045.
35. Gupta S., et al. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 2008, 129:957-968.
36. Rodriguez-Viciana P., et al. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol. Cell. Biol. 2004, 24:4943-4954.
37. Murillo M.M., et al. RAS interaction with PI3K p110α is required for tumor-induced angiogenesis. J. Clin. Invest. 2014, 124:3601-3611.
38. Castellano E., et al. Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance. Cancer Cell 2013, 24:617-630.
39. Kurig B., et al. Ras is an indispensable coregulator of the class IB phosphoinositide 3-kinase p87/p110gamma. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20312-20317.
40. Guillermet-Guibert J., et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:8292-8297.
41. Foukas L., et al. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11381-11386.
42. Kulkarni S., et al. PI3Kbeta plays a critical role in neutrophil activation by immune complexes. Sci. Signal. 2011, 4:ra23.
43. Consonni A., et al. Role and regulation of phosphatidylinositol 3-kinase β in platelet integrin α2β1 signaling. Blood 2012, 119:847-856.
44. Martin V., et al. Deletion of the p110beta isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood 2010, 115:2008-2013.
45. Canobbio I., et al. Genetic evidence for a predominant role of PI3Kbeta catalytic activity in ITAM- and integrin-mediated signaling in platelets. Blood 2009, 114:2193-2196.
46. Okkenhaug K., et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002, 297:1031-1034.
47. Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu. Rev. Immunol. 2013, 31:675-704.
48. Delgado P., et al. Essential function for the GTPase TC21 in homeostatic antigen receptor signaling. Nat. Immunol. 2009, 10:880-888.
49. Saudemont A., et al. p110gamma and p110delta isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:5795-5800.
50. Hale B., et al. Structural insights into phosphoinositide 3-kinase activation by the influenza A virus NS1 protein. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:1954-1959.
51. Geering B., et al. Regulation of class IA PI3Ks: is there a role for monomeric PI3K subunits?. Biochem. Soc. Trans. 2007, 35:199-203.
52. Geering B., et al. Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:7809-7814.
53. Chagpar R., et al. Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:5471-5476.
54. Dou Z., et al. Class IA PI3K p110β subunit promotes autophagy through Rab5 small GTPase in response to growth factor limitation. Mol. Cell 2013, 50:29-42.
55. Chamberlain M.D., et al. Deregulation of Rab5 and Rab4 proteins in p85R274A-expressing cells alters PDGFR trafficking. Cell. Signal. 2010, 22:1562-1575.
56. Chiu Y-H., et al. BRD7, a tumor suppressor, interacts with p85α and regulates PI3K activity. Mol. Cell 2014, 54:193-202.
57. Kuchay S., et al. FBXL2- and PTPL1-mediated degradation of p110-free p85β regulatory subunit controls the PI(3)K signalling cascade. Nat. Cell Biol. 2013, 15:472-480.
58. Comb W.C., et al. p85α SH2 domain phosphorylation by IKK promotes feedback inhibition of PI3K and Akt in response to cellular starvation. Mol. Cell 2012, 45:719-730.
59. Lee J., et al. Inhibition of PI3K binding to activators by serine phosphorylation of PI3K regulatory subunit p85α Src homology-2 domains. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:14157-14162.
60. Cuevas B.D., et al. Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J. Biol. Chem. 2001, 276:27455-27461.
61. Neal C.L., et al. Overexpression of 14-3-3f in cancer cells activates PI3K via binding the p85 regulatory subunit. Oncogene 2011, 31:897-906.
62. Suire S., et al. Gbetagammas and the Ras binding domain of p110gamma are both important regulators of PI(3)Kgamma signalling in neutrophils. Nat. Cell Biol. 2006, 8:1303-1309.
63. Suire S., et al. GPCR activation of Ras and PI3Kc in neutrophils depends on PLCb2/b3 and the RasGEF RasGRP4. EMBO J. 2012, 31:3118-3129.
64. Vadas O., et al. Molecular determinants of PI3Kγ-mediated activation downstream of G-protein-coupled receptors (GPCRs). Proc. Natl. Acad. Sci. U.S.A. 2013, 110:18862-18867.
65. Walser R., et al. PKCβ phosphorylates PI3Kγ to activate it and release it from GPCR control. PLoS Biol. 2013, 11:e1001587.
66. Perino A., et al. Integrating Cardiac PIP(3) and cAMP Signaling through a PKA anchoring function of p110gamma. Mol. Cell 2011, 42:84-95.
67. Miled N., et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science 2007, 317:239-242.
68. Burke J.E., et al. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Proc. Natl. Acad. Sci. U.S.A. 2012, 109:15259-15264.
69. Zhao L., Vogt P. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:2652-2657.
70. Hon W.C., et al. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases. Oncogene 2012, 31:3655-3666.
71. Wu X., et al. Activation of diverse signalling pathways by oncogenic PIK3CA mutations. Nat. Commun. 2014, 5:4961.
72. Rudd M.L., et al. A unique spectrum of somatic PIK3CA (p110alpha) mutations within primary endometrial carcinomas. Clin. Cancer Res. 2011, 17:1331-1340.
73. Hao Y., et al. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions. Cancer Cell 2013, 23:583-593.
74. Kinross K., et al. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J. Clin. Invest. 2012, 122:553-557.
75. Koren S., Bentires-Alj M. Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors. FEBS J. 2013, 280:2758-2765.
76. Yuan W., et al. Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene 2013, 32:318-326.
77. Utermark T., et al. The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes Dev. 2012, 26:1573-1586.
78. Hanker A.B., et al. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:14372-14377.
79. Cheung L., et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov. 2011, 1:170-185.
80. Urick M.E., et al. PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res. 2011, 71:4061-4067.
81. Jaiswal B.S., et al. Somatic mutations in p85a promote tumorigenesis through class IA PI3K activation. Cancer Cell 2009, 16:463-474.
82. Cheung L.W.T., et al. Naturally occurring neomorphic pik3r1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors. Cancer Cell 2014, 26:479-494.
83. Chudasama K.K., et al. SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. Am. J. Hum. Genet. 2013, 93:150-157.
84. Berenjeno I.M., et al. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor. Biochem. J. 2012, 442:151-159.
85. Kan Z., et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466:869-873.
86. Dbouk H.A., et al. Characterization of a tumor-associated activating mutation of the p110β PI 3-Kinase. PLoS ONE 2013, 8:e63833.
87. Deau M-C., et al. A human immunodeficiency caused by mutations in the PIK3R1 gene. J. Clin. Invest. 2014, 124:3923-3928.
88. Zhang J., et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:1398-1403.
89. Cornillet-Lefebvre P., et al. Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110delta mutations. Leukemia 2006, 20:374-376.
90. Puri K.D., et al. B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies. Int. Rev. Immunol. 2013, 32:397-427.
91. Burger J.A. The CLL Cell Microenvironment. Adv. Exp. Med. Biol. 2013, 792:25-45.
92. Burger J.A. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr. Opin. Oncol. 2012, 24:643-649.
93. Tzenaki N., Papakonstanti E.A. p110δ PI3 kinase pathway: emerging roles in cancer. Front. Oncol. 2013, 3:40.
94. Shi Y., et al. Primate-specific miR-663 functions as a tumor suppressor by targeting PIK3CD and predicts the prognosis of human glioblastoma. Clin. Cancer Res. 2014, 20:1803-1813.
95. Bergamini G., et al. A selective inhibitor reveals PI3Kγ dependence of T(H)17 cell differentiation. Nat. Chem. Biol. 2012, 8:576-582.
96. Brazzatti J.A., et al. Differential roles for the p101 and p84 regulatory subunits of PI3Kγ in tumor growth and metastasis. Oncogene 2012, 31:2350-2361.
97. Johnson C., et al. Substitution of feline leukemia virus long terminal repeat sequences into murine leukemia virus alters the pattern of insertional activation and identifies new common insertion sites. J. Virol. 2005, 79:57-66.
98. Becattini B., et al. PI3Kgamma within a nonhematopoietic cell type negatively regulates diet-induced thermogenesis and promotes obesity and insulin resistance. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:E854-E863.
99. Perino A., et al. Combined inhibition of PI3Kβ and PI3Kγ reduces fat mass by enhancing α-MSH-dependent sympathetic drive. Sci. Signal. 2014, 7:ra110.
100. Yu M., et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014, 345:216-220.
101. Vadas O., et al. Structural basis for activation and inhibition of class I phosphoinositide 3-kinases. Sci. Signal. 2011, 4:1-13.
102. Backer J.M. The regulation of class IA PI 3-kinases by inter-subunit interactions. Curr. Top. Microbiol. Immunol. 2010, 346:87-114.
103. Burke J.E., Williams R.L. Dynamic steps in receptor tyrosine kinase mediated activation of class IA phosphoinositide 3-kinases (PI3K) captured by H/D exchange (HDX-MS). Adv. Biol. Regul. 2013, 53:97-110.
104. Burke J.E., et al. Dynamics of the phosphoinositide 3-kinase p110d interaction with p85a and membranes reveals aspects of regulation distinct from p110a. Structure 2011, 19:1127-1137.
105. Zhang X., et al. Structure of lipid kinase p110β/p85β elucidates an unusual SH2-domain-mediated inhibitory mechanism. Mol. Cell 2011, 41:567-578.
106. Mandelker D., et al. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:16996-17001.
107. Dbouk H.A., et al. A biochemical mechanism for the oncogenic potential of the p110β catalytic subunit of phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:19897-19902.
108. Wu H., et al. Regulation of class IA PI 3-kinases: C2 domain-iSH2 domain contacts inhibit p85/p110alpha and are disrupted in oncogenic p85 mutants. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20258-20263.
109. Shymanets A., et al. p87 and p101 subunits are distinct regulators determining class IB PI3K specificity. J. Biol. Chem. 2013, 288:31059-31068.